Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Repression of exogenous gene expression by the retinoic acid target gene G0S2.

Ma T, Dong JP, Sekula DJ, Fei DL, Lamph WW, Henderson M, Lu Y, Blumen S, Freemantle SJ, Dmitrovsky E.

Int J Oncol. 2013 May;42(5):1743-53. doi: 10.3892/ijo.2013.1876. Epub 2013 Mar 28.

2.

The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor.

Li Y, Shen Q, Kim HT, Bissonnette RP, Lamph WW, Yan B, Brown PH.

Breast Cancer Res Treat. 2011 Aug;128(3):667-77. doi: 10.1007/s10549-010-1083-9. Epub 2010 Sep 7.

3.

Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1.

Uray IP, Shen Q, Seo HS, Kim H, Lamph WW, Bissonnette RP, Brown PH.

J Biol Chem. 2009 Jan 2;284(1):345-53. doi: 10.1074/jbc.M804721200. Epub 2008 Oct 28.

4.

G0S2 is an all-trans-retinoic acid target gene.

Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, Cui Q, Gallagher R, Dmitrovsky E.

Int J Oncol. 2008 Aug;33(2):397-404.

5.

Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268.

Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB.

Clin Cancer Res. 2008 Jul 15;14(14):4556-63. doi: 10.1158/1078-0432.CCR-08-0040.

6.

The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis.

Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB.

Mol Cancer Ther. 2008 May;7(5):1251-7. doi: 10.1158/1535-7163.MCT-08-0023.

7.

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.

Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH.

Br J Cancer. 2008 Apr 22;98(8):1380-8. doi: 10.1038/sj.bjc.6604320. Epub 2008 Mar 25.

8.

The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.

Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PH.

Clin Cancer Res. 2007 Oct 15;13(20):6224-31.

9.

Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma.

Hudson AR, Roach SL, Higuchi RI, Phillips DP, Bissonnette RP, Lamph WW, Yen J, Li Y, Adams ME, Valdez LJ, Vassar A, Cuervo C, Kallel EA, Gharbaoui CJ, Mais DE, Miner JN, Marschke KB, Rungta D, Negro-Vilar A, Zhi L.

J Med Chem. 2007 Sep 20;50(19):4699-709. Epub 2007 Aug 17.

PMID:
17705362
10.

Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.

Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH.

Cancer Res. 2006 Dec 15;66(24):12009-18.

11.

A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.

Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW.

Br J Cancer. 2006 Mar 13;94(5):654-60.

12.

Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade.

Wu K, DuPré E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, Brown PH.

Breast Cancer Res Treat. 2006 Mar;96(2):147-57. Epub 2005 Nov 5.

PMID:
16273314
13.

Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.

Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW.

Cancer Lett. 2006 Aug 28;240(2):225-33. Epub 2005 Nov 3.

PMID:
16271436
15.

The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.

Hermann TW, Yen WC, Tooker P, Fan B, Roegner K, Negro-Vilar A, Lamph WW, Bissonnette RP.

Lung Cancer. 2005 Oct;50(1):9-18.

PMID:
15993980
17.

The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.

Kong G, Kim HT, Wu K, DeNardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH.

Cancer Res. 2005 Apr 15;65(8):3462-9.

18.

A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.

Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW.

Clin Cancer Res. 2004 Dec 15;10(24):8656-64.

19.
20.

The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.

Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB.

Cancer Res. 2004 May 15;64(10):3566-71.

22.

Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid.

Farmer LJ, Zhi L, Jeong S, Lamph WW, Osburn DL, Croston G, Flatten KS, Heyman RA, Nadzan AM.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):261-4.

PMID:
12482435
23.

The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.

Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PH.

Cancer Res. 2002 Nov 15;62(22):6376-80.

24.

Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.

Suh N, Lamph WW, Glasebrook AL, Grese TA, Palkowitz AD, Williams CR, Risingsong R, Farris MR, Heyman RA, Sporn MB.

Clin Cancer Res. 2002 Oct;8(10):3270-5.

25.

Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.

Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH.

Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74.

26.
27.
28.

Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.

Gamage SD, Bischoff ED, Burroughs KD, Lamph WW, Gottardis MM, Walker CL, Fuchs-Young R.

J Pharmacol Exp Ther. 2000 Nov;295(2):677-81.

PMID:
11046105
29.

9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.

Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH.

Clin Cancer Res. 2000 Sep;6(9):3696-704.

30.

Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells.

Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, Heyman RA, Chandraratna RA, Shudo K, Hong WK, Lotan R.

Clin Cancer Res. 2000 Apr;6(4):1563-73.

31.

Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.

Bischoff ED, Heyman RA, Lamph WW.

J Natl Cancer Inst. 1999 Dec 15;91(24):2118.

PMID:
10601384
32.
33.

Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW.

Cancer Res. 1998 Feb 1;58(3):479-84.

34.

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.

Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr.

J Natl Cancer Inst. 1998 Jan 21;90(2):124-33.

PMID:
9450572
35.

Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells.

Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RA, Shudo K, Hong WK, Lotan R.

Cancer Res. 1997 Nov 1;57(21):4931-9.

36.
37.

A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation.

Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH Jr.

Blood. 1997 Jun 15;89(12):4282-9.

38.

A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice.

Shalinsky DR, Bischoff ED, Lamph WW, Zhang L, Boehm MF, Davies PJ, Nadzan AM, Heyman RA.

Cancer Res. 1997 Jan 1;57(1):162-8.

39.

Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.

Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA.

Cancer Res. 1996 Dec 15;56(24):5566-70.

40.

Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells.

Zhang L, Nadzan AM, Heyman RA, Love DL, Mais DE, Croston G, Lamph WW, Boehm MF.

J Med Chem. 1996 Jul 5;39(14):2659-63.

PMID:
8709094
41.

Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice.

Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS, Thomazy V, Davies PJ.

Clin Cancer Res. 1996 Mar;2(3):511-20.

42.

The efficacy of 9-cis retinoic acid in experimental models of cancer.

Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA.

Breast Cancer Res Treat. 1996;38(1):85-96. Review.

PMID:
8825126
43.

Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice.

Shalinsky DR, Bischoff ED, Gregory ML, Gottardis MM, Hayes JS, Lamph WW, Heyman RA, Shirley MA, Cooke TA, Davies PJ, et al.

Cancer Res. 1995 Jul 15;55(14):3183-91.

44.

Identification of a nuclear receptor that is activated by farnesol metabolites.

Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, Evans RM, Weinberger C.

Cell. 1995 Jun 2;81(5):687-93.

45.

Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia.

Gleason PE, Jones JA, Regan JS, Salvas DB, Eble JN, Lamph WW, Vlahos CJ, Huang WL, Falcone JF, Hirsch KS.

J Urol. 1993 Jun;149(6):1586-92.

PMID:
7684794
46.
47.

Cross-coupling of AP-1 and intracellular hormone receptors.

Lamph WW.

Cancer Cells. 1991 May;3(5):183-5. Review. No abstract available.

PMID:
1654068
48.

Negative and positive regulation by transcription factor cAMP response element-binding protein is modulated by phosphorylation.

Lamph WW, Dwarki VJ, Ofir R, Montminy M, Verma IM.

Proc Natl Acad Sci U S A. 1990 Jun;87(11):4320-4.

49.

mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element.

Ivashkiv LB, Liou HC, Kara CJ, Lamph WW, Verma IM, Glimcher LH.

Mol Cell Biol. 1990 Apr;10(4):1609-21.

50.

fos-jun conspiracy: implications for the cell.

Verma IM, Ransone LJ, Visvader J, Sassone-Corsi P, Lamph WW.

Ciba Found Symp. 1990;150:128-37; discussion 137-46. Review.

PMID:
2115424

Supplemental Content

Loading ...
Support Center